Sudeep Kumar

About

I have over 15 years research experience in the areas of microbiology and immunology. Specifically, my research is focused on the development of novel vaccines for bacterial and viral pathogens. By utilizing human Fc gamma receptor targeting approach I have demonstrated enhancement of efficacy of subunit vaccines against pulmonary infections including Streptococcus pneumoniae and Venezuelan Equine Encephalitis Virus. Moreover, my research provided knowledge to enhance the efficacy of Francisella tularesnsis vaccines. Utilizing whole cell and inactivated vaccine platforms I have demonstrated that dendritic cell maturation factors can significantly enhance the efficacy of F tularensis live vaccine strain. My current research interests include vaccine development, vaccine adjuvants and resident memory T cells.

Employment

• Albany Medical College Instructor
  2020 - Present
• Albany Medical College Post Docotoral Fellow
  2013 - 2020
• New Mexico VA Health Care System Research Assistant
  2011 - 2013
• Rajendra Memorial Research Institute of Medical Sciences Senior Research Fellow
  2007 - 2011
• Rajendra Memorial Research Institute of Medical Sciences Junior Research Fellow
  2003 - 2007
• Bose Institute Junior Research Fellow
  2003 - 2003
• Pandit Ravishankar Shukla University Lecturer
  2002 - 2002

Education

• Jadavpur University PhD
  2004 - 2011
• Pandit Ravishankar Shukla University MSc.
  2000 - 2002
• Pandit Ravishankar Shukla University BSc
  1997 - 2000

Projects & Funding

Projects & funding information is unavailable.

Publications (25)

• Mucosal immunity elicited by a human-Fcγ receptor-I targeted intranasal vaccine platform enhances resistance against nasopharyngeal colonization of Streptococcus pneumoniae and induces broadly protective immunity against respiratory pathogens
  Vaccine 2025 DOI: 10.1016/j.vaccine.2025.126729
  +Save
• A bacterial vesicle-based pneumococcal vaccine against influenza-mediated secondary Streptococcus pneumoniae pulmonary infection
  Mucosal Immunology 2024 DOI: 10.1016/j.mucimm.2024.01.002
  +Save
• SARS-CoV-2: Immunity, Challenges with Current Vaccines, and a Novel Perspective on Mucosal Vaccines
  Vaccines 2023 DOI: 10.3390/vaccines11040849
  +Save
• The O-Ag Antibody Response to Francisella Is Distinct in Rodents and Higher Animals and Can Serve as a Correlate of Protection
  Pathogens 2021 DOI: 10.3390/pathogens10121646
  +Save
• Autotransporter-Mediated Display of Complement Receptor Ligands by Gram-Negative Bacteria Increases Antibody Responses and Limits Disease Severity
  Pathogens 2020 DOI: 10.3390/pathogens9050375
  +Save
• Preclinical Efficacy of a Trivalent Human FcγRI-Targeted Adjuvant-Free Subunit Mucosal Vaccine against Pulmonary Pneumococcal Infection
  Vaccines 2020 DOI: 10.3390/vaccines8020193
  +Save
• Bacterial Protein Toll-Like-Receptor Agonists: A Novel Perspective on Vaccine Adjuvants
  Frontiers in Immunology 2019 DOI: 10.3389/fimmu.2019.01144
  +Save
• Live-Attenuated Bacterial Vectors for Delivery of Mucosal Vaccines, DNA Vaccines, and Cancer Immunotherapy
  Environmental Chemistry for a Sustainable World 2019 DOI: 10.1007/978-3-030-01881-8_2
  +Save
• Evaluation of an outbred mouse model for Francisella tularensis vaccine development and testing
  PLOS ONE 2018 DOI: 10.1371/journal.pone.0207587
  +Save
• Differential In Vitro Cultivation of Francisella tularensis Influences Live Vaccine Protective Efficacy by Altering the Immune Response
  Frontiers in Immunology 2018 DOI: 10.3389/fimmu.2018.01594
  +Save